PD-1 expression	Urothelial Cancer	PD-1 expression	Urothelial Cancer	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3	pembrolizumab + GSK3359609 Sensitive: C3 – Early Trials pembrolizumab + GSK3359609 Sensitive : C3
TISvopra	Non Small Cell Lung Cancer	TISvopra	Non Small Cell Lung Cancer	JTX-4014 + JTX-2011 Sensitive: C3 – Early Trials JTX-4014 + JTX-2011 Sensitive : C3	JTX-4014 + JTX-2011 Sensitive: C3 – Early Trials JTX-4014 + JTX-2011 Sensitive : C3

ICOS agonist

Associations(3)